Trinity Biotech Files Routine 6-K Report

Ticker: TRIB · Form: 6-K · Filed: Apr 5, 2024 · CIK: 888721

Trinity Biotech PLC 6-K Filing Summary
FieldDetail
CompanyTrinity Biotech PLC (TRIB)
Form Type6-K
Filed DateApr 5, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 6-k, reporting

TL;DR

Trinity Biotech filed its monthly 6-K, just a routine check-in, no big news.

AI Summary

Trinity Biotech plc filed a Form 6-K on April 5, 2024, to report its activities for the month of April 2024. The company, based in Ireland, is a foreign private issuer and files under the 1934 Act. This filing does not contain specific financial figures or operational updates beyond its routine reporting status.

Why It Matters

This filing indicates Trinity Biotech plc is fulfilling its regular reporting obligations as a foreign private issuer with the SEC, providing transparency to investors.

Risk Assessment

Risk Level: low — This is a routine filing by a foreign private issuer and does not contain new material information or financial results.

Key Players & Entities

  • TRINITY BIOTECH PLC (company) — Registrant
  • 0000888721 (company) — Central Index Key
  • 2835 (company) — Standard Industrial Classification
  • April 5, 2024 (date) — Filing Date

FAQ

What type of company is Trinity Biotech plc?

Trinity Biotech plc is classified under the Standard Industrial Classification code 2835, which pertains to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.

When was this Form 6-K filed?

This Form 6-K was filed on April 5, 2024.

Is Trinity Biotech plc required to file Form 20-F?

Yes, the filing indicates that Trinity Biotech plc files annual reports under cover of Form 20-F.

Where is Trinity Biotech plc's principal executive office located?

Trinity Biotech plc's principal executive office is located at IDA Business Park, Bray, Co. Wicklow, Ireland.

What is the purpose of a Form 6-K filing?

A Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to report information that the registrant has made or is required to make public in its home country or has submitted or is required to submit to its home country exchange.

Filing Stats: 286 words · 1 min read · ~1 pages · Grade level 13.7 · Accepted 2024-04-05 13:05:21

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLC Trinity Biotech plc (Registrant) By: /s/ Des Fitzgerald Des Fitzgerald Interim Chief Financial Officer Date: April 5, 2024

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.